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Abstract:  Human Immunodeficiency Virus (HIV) was first related with Acquired Immunodeficiency Syndrome (AIDS) in 1983, and since then 
many attempts have been made to treat, control and in the last couple of years several studies have been conducted with the intention of achieve 
a cure or at least a functional cure. 
The understanding of the replication of the virus, has lead a new course of investigation regarding the best treatment options defined with, when 
to treat and how to treat to achieve the better response regarding the full and fast recover of the patient’s immune response. In this regard several 
strategies have been presented and discussed through the years, like the initial treatment for one side and the maintenance treatment for other 
side. 
The authors present a review of the state of the art and the perspective of treatments according the steps of the replication of the virus reflected in 
the immunological status of the patient. 
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INTRODUCTION 
Human Immunodeficiency Virus (HIV) was first related 
with Acquired Immunodeficiency Syndrome (AIDS) in 
1983 by Barré-Sinoussiof Pasteur Institute, who named it 
Lymphadenopathy Associated Virus (LAV)
1
 and, 
subsequently, in 1984 by Marx J.L. of National Cancer 
Institute, as HTLV-III
2
. However, only in 1986
3
, in a joint 
conference, the nomenclature would be made official as 
HIV and was declared as responsible for AIDS. 
 
However, its origin points to the 20s of the last century in 
the Democratic Republic of Congo where the Simian 
Immunodeficiency Virus (SIV) in chimpanzees
4,5,6
suffered a 
new mutation being transmitted to mankind. It was followed 
by an “incubation” period up to the 70s, perhaps dictated by 
the difficulty of traveling. 
 
Since 1978-80 this syndrome, whose first definition by the 
Atlanta’s CDC was "a disease, at least moderately predictive 
of a defect in cellular immunity, occurring in a person with 
no apparent reason known for this decrease"
7
, has been 
occupying a place in history for its pandemic distribution 
and associated morbidity. 
 
Treatment wise, from "hit strong - hit hard" in 1996
8
 
(abandoned due to high toxicity and low drug robustness), 
through the consensus of the years 2000 to treat if CD4
+
 T 
lymphocytes ≤ 350 cells/mL until today with "if it's there-
treat!", aided by more effective, robust, less toxic and about 
25 different drugs available, the problem is not what to treat 
but how to treat for quality longevity. 
THE VIRUS 
Being a Lentivirus of the Retroviridae family, like others of 
this genus, is responsible for a disease with a long 
incubation time
9
.HIV is a complex 120nm spherical 
structure formed by glycoproteins on its surface with a 
phospholipid envelope that protects a viral conic capsid 
which in turn protects the core with two single-stranded 
positive viral RNA strands, and enzymes (reverse 
transcriptase, protease, ribonuclease and integrase) that will 
be required for decoding upon entry into the cell
10
. 
 
After migrating into the cell, it begins by replicating in 
double-stranded DNA by reverse transcriptase (one of the 
enzymes in the capsule) and later, by integration into the 
cellular DNA by the integrase, which will lead to the 
activation of the cell apoptosis, with direct repercussions on 
the host's time and quality of life. However, it is only after 
the cleavage process by the protease followed by the 
assembly that new viruses are in fact capable of being 
released into the bloodstream
11
. 
 
Two types of viruses were identified, HIV-1 and HIV-2
12
. 
HIV-1 is most virulent and responsible for most infections 
globally, while the slower-evolving HIV-2 is mostly 
restricted to West Africa
13
. 
THE DRUGS 
In 2010 the usage of antiretroviral therapy (ART), and 
according to the United States National Institutes of Allergy 
and Infectious Diseases, almost 700,000 lives were saved
14
, 
their aim is to reduce the viral load to permit the restoration 
of the immune system, avoiding the risk of opportunistic 
diseases, and by controlling viral replication the HIV 
becomes a chronic controllable disease
15
. 
However, the need for daily therapies, sometimes in 
complex regimens, the potential for toxicities and resistance 
are some of the challenges still unsolved. Zidovudine 
(AZT), a nucleoside reverse transcriptase inhibitor (NRTI or 
nuc), was the first effective treatment of this infection 
approved by the FDA in 1987 due to results in symptomatic 
control
16
. With the development of other molecules to 
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improve therapeutic response, mono therapy with AZT was 
abandoned in 1992 and combined regimens were initiated
17
. 
However, they failed to maintain a sustained rise of the 
CD4
+
 T lymphocytes.  
 
In 1995 in Vancouver, and as published two years later in 
The New England Journal of Medicine, the results of 
combination antiretroviral therapy (acting simultaneously 
against different phases/stages of the HIV life cycle) of two 
nucs (AZT plus lamivudine (3TC)) and a protease inhibitor 
(PI) (indinavir (IDV))
18
 showed a decrease in the incidence 
of opportunistic infections and AIDS mortality
19
. This 
therapy would then be known as Highly Active Anti-
Retroviral Therapy (HAART) and maintains, until today, as 
the paradigm of HIV treatment. 
 
Based on the viral cycle, there are 4 therapeutic classes, 
each with specific actions at certain stage of the replication 
sequence, and their combination is now advised by different 
international guidelines (DHHS
20
, EACS
21
, DGS/CNLS
22
). 
 
Starting with the entry/fusion inhibitors, whose actions lead 
to inhibition of the processes of fusion and entry of the virus 
into the cell
23
. This family includes enfuvirtide, also known 
as T-20, and maraviroc (MVC), with new drugs being 
studied at the moment. 
Although acting at the same stage of the cycle, these two 
drugs have a very distinct mechanism of action. While T-20 
is a peptide drug, used intramuscularly, interacting with the 
glycoprotein gp41 to form inactive helix bundles preventing 
activation of the fusion complex between virus and cell 
membrane
23
; MVC binds to the T lymphocyte receptor 
complex, CCR5, directly inhibiting viral fusion with the 
cell
23
. Its use requires the evaluation of cellular tropism, 
since in cells with CXCR4 receptors it cannot be used. 
Nevertheless, it should be noted that HIV can both use the 
CCR5 receptor and CXCR4 to enter the cell. 
 
Reverse transcriptase inhibitors are the oldest therapeutic 
class in use, and are commonly called "backbones" for being 
the support of the remaining classes. They act in the RNA 
transcription phase to DNA as terminator chains competing 
with other nucleosides
23
.This class is divided into 
nucleosides/nucleotides (nucs) and non-nucleosides (non-
nucs).  
 
Nowadays, the most commonly used nucs are abacavir 
(ABC), lamivudine (3TC), tenofovir (TDF - single 
nucleotide to date) and emtricitabine (FTC - lamivudine 
analogue); though, AZT, despite its toxicity problems, is 
still used in the prevention of vertical transmission and in 
salvage/rescue schemes. 
 
Non-nucs on the other hand, act by binding to the allogeneic 
site of the enzyme in a noncompetitive inhibitory mode
23
. 
Examples are nevirapine (NVP), efavirenz (EFV), etravirine 
(ETR) and more recently rilpivirine (RPV). Others are 
currently under investigation, and of these, doravirine 
(DOR) (nevirapine analogue) shows the most promising 
data. 
 
Another class being used is the protease inhibitors, 
responsible for the initiation of HAART, act by inhibiting 
the cleavage of RNA long chains leading to defective 
particles without infecting potential
23
. Atazanavir (ATZ), 
lopinavir (LPV) and darunavir (DRV) are currently the most 
commonly used. However, these require the use of a booster 
(PI/b) to increase therapeutic action, usually ritonavir (RTV) 
or cobicistat (COBI - a "pure" P450 cytochrome inducer 
devoid of anti-retroviral activity). Protease inhibitors have 
higher robustness and so a high genetic barrier (number of 
mutations necessary for a drug to stop acting). 
 
Similar to these, maturation inhibitors (MI) must be 
considered, which after a process of regression due to bad 
results presented in 2010, made a comeback to research 
again, this time with promising results. 
 
The last class to enter the therapeutic armament was 
integrase strand transfer inhibitors, also known as nuclear 
integrase chain transfer inhibitors (NICTI or InSTI). The 
first one approved was raltegravir (RAL) in 2007, followed 
by elvitegravir (EVG) in 2014 and more recently 
dolutegravir (DTG)
23
. Their capacity to rapidly decrease 
viral load makes them the most potent treatment of HIV 
infection. However, is important to point that EVG needs a 
booster to have an effective action, a PI (RTV or other) or 
most commonly COBI (as part of a single tablet regime 
(STR)). By inhibiting viral genome integration into the 
human one preserves the initial cellular viability
23
. 
COMBINED ANTIRETROVIRAL TREATMENT 
The purpose of combining various active drugs is to 
eliminate viral "escape" and to hinder the induction of 
resistance
20,21,22,23, 
so the immune response could be 
recovered and established. Although theoretically correct, 
this concept is fallible, since resistance to only one of the 
drugs may incapacitate the complete therapeutic action on 
viral suppression. 
 
Several studies were performed to assess the number of 
drugs required to maintain maximum efficacy, but none 
have provided the answer, knowing only that to control a 
patient at an early stage [naïve], one drug is not enough, but 
5 or more have no greater effectiveness bringing only 
highertoxicity
24,25
. 
 
Another important fact is that to maintain a functioning 
therapy, treatment adherence is crucial. For this purpose, 
various drugs have been studied in successful STRs and 
others for long time of action (extended release 
formulations), but in this case the need for injectable routes 
of administration causing discomfort and possible higher 
risk of toxicity due to the lack of effective antidotes are 
some of the problems encountered. 
THE "GUIDELINES" 
Knowing that we have drugs that satisfy these purposes, the 
question remains - how to treat patients, where to put the 
drug A or B and what is its surplus value? 
 
In order to answer this question, we need to understand HIV 
life cycle, and, in the light of current knowledge, it is not 
necessary for the virus to always run its "assembly line" to 
replicate, since after the DNA integration, such process is 
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independent
26
 which helps to explain the continuous 
expression of viruses in the late presenters, otherwise the 
“zero-replication” value would be achieved whenever the 
patient reached values of 1 or virtually zero CD4
+
T cells. 
 
Regarding naïve patients, we know there are some regimens 
that don’t work, although in theory they are very desirable. 
Several studies have been done using T-20 or, more recently 
MVC, the latter, combined with TDF/FTC
27
, RAL
28
or 
boosted DRV
29
, which did not show the same efficacy when 
compared with traditional regimens with 2 nucs plus a non-
nuc, PI or INSTI. 
 
But, if in these cases the results were not as expected, the 
same cannot be said when using a combination of 2 nucs 
plus1 non-nucs.  
 
Aside being the oldest, or at least more experienced being 
the combination more used until now, and still in use in 
some guidelines, AZT/3TCplus EFV was gradually replaced 
by ABC/3TC and TDF/FTC plus EFV, due to reasons of 
significant AZT and EFV toxicity and not effectiveness.  
 
With so, the "old" question of which set of nucs to choose 
has been a problem for years. And, if D:A:D
30
 study raised 
some doubts about ABC, the development of tenofovir 
alaphenamide fumarate (TAF - the pro-drug of TDF) 
emerged those of long-term use of TDF
31
. Thus, the answer 
to this simple question is not totally consensual, but it must 
be noted that in the future, this class of drugs will require 
reanalysis, taking into account its toxicities or, therefore, 
will naturally be replaced by other classes
32
.Another 
problem with this class is the low affinity for enzyme-
blocking, which leads to successive "escape" problems and 
induce-resistances, fundamentally in poor adherent patients. 
 
Non-nucs have a similar problem. Except for nevirapine, the 
great characteristic of these drugs is the long-time of action 
and its simplicity of dosage permitting their use in STR or 
once daily regimens. However, the resistance problem 
seems to be less severe if we consider ETR
33
 and DOR
34
, the 
latter still being studied. Regarding RLP, the difficulty 
imposed by the limitations of its use (CD4
+
T cells>200 
cells/mL and HIV RNA<100,000cps/mL), caloric input 
conditions (>500 Kcal), interactions with proton pump 
inhibitors and its genetic barrier
35
 coupled with the baseline 
prevalence of the E138 mutation, condition its use, although 
it allows, like others of this family, one-tablet co-
formulation with TDF or TAF/FTC. On the other hand, the 
high number of late presenters, with high viral loads and low 
CD4
+
T counts are not uncommon, creating limitations for its 
use in real world settings
20,21,22,35
. For these reasons, the use 
of these two therapeutic classes [nucs and non-nucs] need a 
reanalysis or otherwise will be predestined to a future 
failure. 
 
Notwithstanding the nucs problem over time, these have 
been used as an essential part of therapeutic combinations – 
“backbones”.  
The oldest regime of all and with a major therapeutic 
success was undoubtedly its use with boosted PIs; a 
combination that is both strong and fragile due a high 
genetic barrier but the pill burden that is not yet what is 
desired. Nevertheless, this strategy could change with the 
introduction of the STR of DRV/c/TAF/FTC witch has 
presented good results in clinical trials
36
. 
 
Another problem of this combination is the intrinsic 
properties of their drugs and their toxic potential, since the 
boosted PIs (although the latter, namely ATZ and DRV in 
favor to DRV
37
, are less toxic) lead to the early development 
of metabolic syndrome
38
, controllable in youngsters but 
difficult to manage in the elderly due to inherent 
comorbidities. On the other hand, its cumulative use with 
nucs increases this potential for toxicity
39
. 
 
The most recent class of drugs is the In STI as said. They 
are the most attractive class, nowadays, for treatment 
initiation in naïve patients
40
 due to their high potency and 
mechanism of action, which could prevent viral 
dissemination into biological sanctuaries and therefore, 
could be an important key to achieve sustained virological 
response or, even, a cure. 
 
The ease of its combination with virtually all other classes 
put them on a plateau above. Their potency and 
robustness
40
, especially with DTG
41,42
, seems to be better 
since the binding to the integrase is much more durable and 
robust than other classes to their respective enzymes, 
especially the nucs, aside they keep showing good efficacy 
and tolerability over the years of use. All, of these factors 
make this class a very promising choice for the future, for 
naïves or experimented patients or even more after results of 
their use in nuc-sparing regimes where, fundamentally, 
RAL
43,44,45,46,47,48,49
and DTG
50,51,52,53
, assume a prominent 
position for a comfortable backbone substitution considering 
the maintenance treatment of virologically suppressed HIV-
1 infection; or in a nuc-light regimes, namely 
DTG+3TC
54,55,56
 also in the same conditions as above. 
WHAT TO CHOOSE AND HOW? 
However, with all these options, the major problem is how 
to treat the infected patient for a long period of time, 
allowing him to live longer and better.  
 
And so, while the toxicity seems to be partially solved, the 
question of what and when to use is far from settled. 
IMMUNITY, VIRAL CYCLE AND SANCTUARIES 
For now, the discussion of maintenance therapies in 
suppressed patients, for simplicity and/or decreased 
toxicities, it’s important to pause, and reflect that if in 
patients with good immunity there is no shortage of options, 
in late presenters, options are restricted. 
 
In this matter, two concepts can be created. The first is to 
prevent HIV integration into the healthy cell genome by 
maintaining near-normal immunity with consequent 
decrease of complications that would alter the patient's time 
and quality of life as demonstrated by the Temprano
57
 and 
Stacato
58,59
 studies that led to the global recommendation 
initiation of treatment regardless of the immune stage. 
 
The second is to consider that the virus infects the cell only 
once and does not need to complete replication cycle 
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repeatedly. Once integrated into the cellular genome its 
replication and dissemination into the blood stream is 
continuous with active potential in the sanctuaries
60,61
. This 
is extremely important since the attainment of sanctuaries 
and the degree of virus replication in them seems to 
determine the degree of resistance development and 
potential clinical stabilization of the patient. 
 
So, viral replication dynamics are typically measured in 
populations of infected cellsleading to low levels of CD4
+
 T 
cells (lowering the CD4
+
/CD8
+
 ratio) through a number of 
mechanisms, including pyroptosis of abortively infected 
CD4
+
 T cells,
62
 apoptosis of productively infected CD4
+
 T 
cells,
63
 and killing of infected CD4
+
 T cells by CD8
+
 
cytotoxic lymphocytes that recognize productively infected 
cells.
64
 By this passway, when CD4
+
 T cell numbers decline 
below a critical level, cell-mediated immunity is lost, and 
the body becomes progressively more susceptible to 
opportunistic infections. According to this, the 
determinations of immune stage, has been the support for 
initiation of primary prophylaxis and in the recent past, even 
the beginning of antiretroviral therapy, and is obtained by 
the quantification of CD4
+
 T lymphocytes or by the 
calculating CD4
+
/CD8
+
 ratio in peripheral blood. One of the 
main goals of therapy is to obtain and maintain a CD4
+
 T 
lymphocyte count above 500/mL or CD4
+
/CD8
+
 ratio above 
1, which is the threshold for implying of the maintenance of 
the healthy cell. Gradually lower values [below 500 
CD4
+
/mL or below 1] translate into greater depletion of the 
immune response by increasing the patient's vulnerability to 
opportunistic infections
65
, morbidity and mortality
66
, a 
problematic picture in late presenters where the number of 
"contaminated" cells will replicate as such. 
STEP-WISE THERAPY 
As explain above, the viral replication dynamics are 
typically measured in populations of infected cells, namely 
CD4
+
 T cells or by CD4
+
/CD8
+
 ratio. Assuming the two 
concepts, in patients with good immune status, with CD4
+
 T 
lymphocyte greater than 500/mL or a CD4
+
/CD8
+
 ratio 
above 1, makes sense to adopt a protective strategy of the 
cellular genome, preventing the integration of the virus, in 
which case Is plausible to assume that there are two 
primordial therapeutic classes: InSTIand NNRTI as the third 
agent, combine together whenever possible or with nucs. 
 
In patients with weakened immune stage [below 500 
CD4
+
/mL or a CD4
+
/CD8
+
 ratio below 1], the use of drugs 
whose mechanism of action interferes with the viral 
replicative phase after the virus cell is matured or at the 
phase of assembling should be considered, namely PI or NI 
as a third agent aside the backbone structure (nucs or InSTI). 
WHAT TO DO WHEN LATE PRESENTERS 
RECOVER IMMUNITY? 
Assuming immunological recovery with viral suppression, it 
will be advisable to apply therapies as defined for patients 
with more than 500 CD4
+
/mL or a CD4
+
/CD8
+
 ratio above 
1, that is, the mechanism of action is in the first phase of the 
replicative cycle and a contrary attitude should be applied in 
patients whose stage immune response to values below 500 
CD4
+
/mL. This strategy could prevent new infections of the 
genome in the first case or the release and supply of the 
sanctuaries in the latter case possibilitating the mainstream 
of the therapy that is maintain the patients as healthier as 
possible for a long period of time. 
CONCLUSION 
It should be admitted that although there are still no 
conclusive studies, we can deduce that patients should be 
divided or grouped according to their immunological status 
for therapeutic considerations. In patients with CD4
+
T cells 
above 500 cells/mL the indication would be blocking viral 
DNA integration into human cells as this will decrease the 
degree of invasiveness sanctuaries allowing more uninfected 
cells to exist and proliferate. On the other hand, patients 
with T CD4
+
 cells lower than 500 cells/mL and, 
fundamentally, lower than 200cells/mL, where most of the 
immune system is already compromised, it’s important to 
act in the third phase of the cycle since viral DNA is already 
integrated into the nucleus. It’s necessary that the virus does 
not feasibly reach the bloodstream until there is an effective 
immune recovery (>500 CD4+T/mL) after which, the 
therapeutic switch should be considered, and the same 
strategy should be taken as for the treatment of naïves with 
"conserved" immunities. 
 
We may also consider that drugs such as non-nucs or INSTI 
should be preferred for the treatment of naïve patients with 
lymphocytes T CD4
+
> 500 cells/mL, whereas boosted PIs-
based therapy should preferably to late presenter’s situations 
or for those situations where adherence cannot be 
guaranteed. However, we should be aware that the use of 
boosted PIs in patients with normal immunities, although 
very robust and with good disease control, cannot block the 
integration of viral DNA so that in cell division/replication - 
the cellular apoptosis - will not be compromised, and then 
the patient's survival altered. 
 
In the field of adhesion, DTG and EVG with single-dose co-
formulations may provide, yet, another and good therapeutic 
weapon for naïve patients with "preserved" immunity, with 
adhesion problems. 
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